Viselkedési mintázatok vizsgálata a bazális ganglionok és a limbikus rendszer átfedésében

Translated title of the contribution: Behavioural aspects of a modified crosstalk between basal ganglia and limbic system in Parkinson’s disease

Orsolya Györfi, Helga Nagy, Magdolna Bokor, S. Kéri

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Dysfunctions in dopaminergic neurotransmission lead to motor symptoms and cognitive impairments associated with behavioural disturbances. Parkinson’s disease is a neurodegenerative disorder which is primarily characterized by an abnormal basal ganglia activity. Recently, increased attention has been directed towards the hippocampus in the development of non-motor symptoms. Given the temporal progression of the disease, dopaminergic depletion firstly affects the dorsal striatum leaving the ventral striatum relatively intact. However, it is possible that the structure and function of the hippocampus shows alterations even in early stages of Parkinson’s disease. Subtle cognitive impairments occur in the earliest stages, and therefore Parkinson’s disease could provide a unique model to investigate the effect of replacement therapies on a neural network with different baseline dopaminergic levels. Strong evidence suggests that dopaminergic medications improve the motor symptoms, but these medications might have disadvantageous effects on cognitive functions. In this review, we examine the role of dopaminergic changes across several cognitive and behavioural impairments observed in Parkinson’s disease, with a special reference to hippocampal dysfunctions.

Original languageHungarian
Pages (from-to)87-92
Number of pages6
JournalNeuropsychopharmacologia Hungarica
Volume18
Issue number2
Publication statusPublished - Jun 1 2016

Fingerprint

Limbic System
Basal Ganglia
Parkinson Disease
Hippocampus
Synaptic Transmission
Neurodegenerative Diseases
Cognition
Disease Progression
Cognitive Dysfunction
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Neuropsychology and Physiological Psychology
  • Clinical Neurology

Cite this

Viselkedési mintázatok vizsgálata a bazális ganglionok és a limbikus rendszer átfedésében. / Györfi, Orsolya; Nagy, Helga; Bokor, Magdolna; Kéri, S.

In: Neuropsychopharmacologia Hungarica, Vol. 18, No. 2, 01.06.2016, p. 87-92.

Research output: Contribution to journalReview article

@article{12e9f15925af432a8c6bf68209596172,
title = "Viselked{\'e}si mint{\'a}zatok vizsg{\'a}lata a baz{\'a}lis ganglionok {\'e}s a limbikus rendszer {\'a}tfed{\'e}s{\'e}ben",
abstract = "Dysfunctions in dopaminergic neurotransmission lead to motor symptoms and cognitive impairments associated with behavioural disturbances. Parkinson’s disease is a neurodegenerative disorder which is primarily characterized by an abnormal basal ganglia activity. Recently, increased attention has been directed towards the hippocampus in the development of non-motor symptoms. Given the temporal progression of the disease, dopaminergic depletion firstly affects the dorsal striatum leaving the ventral striatum relatively intact. However, it is possible that the structure and function of the hippocampus shows alterations even in early stages of Parkinson’s disease. Subtle cognitive impairments occur in the earliest stages, and therefore Parkinson’s disease could provide a unique model to investigate the effect of replacement therapies on a neural network with different baseline dopaminergic levels. Strong evidence suggests that dopaminergic medications improve the motor symptoms, but these medications might have disadvantageous effects on cognitive functions. In this review, we examine the role of dopaminergic changes across several cognitive and behavioural impairments observed in Parkinson’s disease, with a special reference to hippocampal dysfunctions.",
keywords = "Cognitive function, Dopaminergic neurotransmission, Hippocampus, Parkinson’s disease",
author = "Orsolya Gy{\"o}rfi and Helga Nagy and Magdolna Bokor and S. K{\'e}ri",
year = "2016",
month = "6",
day = "1",
language = "Hungarian",
volume = "18",
pages = "87--92",
journal = "Neuropsychopharmacologia Hungarica",
issn = "1419-8711",
publisher = "Hungarian Association of Psychopharmacology",
number = "2",

}

TY - JOUR

T1 - Viselkedési mintázatok vizsgálata a bazális ganglionok és a limbikus rendszer átfedésében

AU - Györfi, Orsolya

AU - Nagy, Helga

AU - Bokor, Magdolna

AU - Kéri, S.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Dysfunctions in dopaminergic neurotransmission lead to motor symptoms and cognitive impairments associated with behavioural disturbances. Parkinson’s disease is a neurodegenerative disorder which is primarily characterized by an abnormal basal ganglia activity. Recently, increased attention has been directed towards the hippocampus in the development of non-motor symptoms. Given the temporal progression of the disease, dopaminergic depletion firstly affects the dorsal striatum leaving the ventral striatum relatively intact. However, it is possible that the structure and function of the hippocampus shows alterations even in early stages of Parkinson’s disease. Subtle cognitive impairments occur in the earliest stages, and therefore Parkinson’s disease could provide a unique model to investigate the effect of replacement therapies on a neural network with different baseline dopaminergic levels. Strong evidence suggests that dopaminergic medications improve the motor symptoms, but these medications might have disadvantageous effects on cognitive functions. In this review, we examine the role of dopaminergic changes across several cognitive and behavioural impairments observed in Parkinson’s disease, with a special reference to hippocampal dysfunctions.

AB - Dysfunctions in dopaminergic neurotransmission lead to motor symptoms and cognitive impairments associated with behavioural disturbances. Parkinson’s disease is a neurodegenerative disorder which is primarily characterized by an abnormal basal ganglia activity. Recently, increased attention has been directed towards the hippocampus in the development of non-motor symptoms. Given the temporal progression of the disease, dopaminergic depletion firstly affects the dorsal striatum leaving the ventral striatum relatively intact. However, it is possible that the structure and function of the hippocampus shows alterations even in early stages of Parkinson’s disease. Subtle cognitive impairments occur in the earliest stages, and therefore Parkinson’s disease could provide a unique model to investigate the effect of replacement therapies on a neural network with different baseline dopaminergic levels. Strong evidence suggests that dopaminergic medications improve the motor symptoms, but these medications might have disadvantageous effects on cognitive functions. In this review, we examine the role of dopaminergic changes across several cognitive and behavioural impairments observed in Parkinson’s disease, with a special reference to hippocampal dysfunctions.

KW - Cognitive function

KW - Dopaminergic neurotransmission

KW - Hippocampus

KW - Parkinson’s disease

UR - http://www.scopus.com/inward/record.url?scp=84979085494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979085494&partnerID=8YFLogxK

M3 - Review article

VL - 18

SP - 87

EP - 92

JO - Neuropsychopharmacologia Hungarica

JF - Neuropsychopharmacologia Hungarica

SN - 1419-8711

IS - 2

ER -